Top

25-09-2024 | Cancer Therapy | Review

Return to Intended Oncological Therapy: State of the Art and Perspectives

Authors: Nicolas A. Cortes-Mejia, Heather A. Lillemoe, Juan P. Cata

Abstract

Purpose of the Review

Despite advances in surgical procedures, cancer recurrence still affects a substantial proportion of patients for whom surgery is considered a curative therapy. This review aims to provide a comprehensive overview of RIOT, addressing its definition, influencing factors, and clinical implications.

Findings

RIOT can be defined as a continuous variable as the time from surgery to initiation of adjuvant therapies or categorically as whether patients can successfully receive adjuvant therapies or not. Factors influencing RIOT are age, sex, socioeconomic status, access to healthcare, physical performance and comorbidities, and quality of anesthesia and surgical care.

Summary

Adjuvant therapies such as chemotherapy, radiotherapy, and immunotherapy are often administered to reduce the risk of recurrence after surgery and improve survival. Return to intended oncologic therapy (RIOT) has emerged as a promising outcome metric reflecting patients’ functional recovery after surgery and their ability to receive adjuvant therapies.

Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

Early Breast Cancer Trialists’, Collaborative G, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.CrossRef

Flores RM, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–6. https://doi.org/10.1016/j.jtcvs.2007.10.054.CrossRefPubMed

Gronchi A, et al. Variability in patterns of recurrence after resection of primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS Working Group. Ann Surg. 2016;263(5):1002–9. https://doi.org/10.1097/SLA.0000000000001447.CrossRefPubMed

Mahvi DA, et al. Local Cancer recurrence: the realities, challenges, and opportunities for New therapies. CA Cancer J Clin. 2018;68(6):488–505. https://doi.org/10.3322/caac.21498.CrossRefPubMedPubMedCentral

Pfister D, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65(6):1034–43. https://doi.org/10.1016/j.eururo.2013.08.013.CrossRefPubMed

Subotic D, Van Schil P, Grigoriu B. Optimising treatment for post-operative lung cancer recurrence. Eur Respir J. 2016;47(2):374–8. https://doi.org/10.1183/13993003.01490-2015.CrossRefPubMed

Cescon DW, et al. Therapeutic targeting of minimal residual disease to prevent late recurrence in hormone-receptor positive breast Cancer: challenges and New approaches. Front Oncol. 2021;11:667397. https://doi.org/10.3389/fonc.2021.667397.CrossRefPubMed

10.

Jacome AA, Johnson B. Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack? Cells, 2023. 12(7)10.3390/cells12071068.

11.

de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma. J Clin Oncol. 2009;27(9):1413–8. https://doi.org/10.1200/jco.2008.17.5604.CrossRefPubMed

12.

Sakuramoto S, et al. Adjuvant chemotherapy for gastric Cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20. https://doi.org/10.1056/NEJMoa072252.CrossRefPubMed

13.

Group NM-aC, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77. https://doi.org/10.1016/s0140-6736(10)60059-1.CrossRef

14.

Neoptolemos JP, et al. Adjuvant chemotherapy with Fluorouracil Plus Folinic Acid vs Gemcitabine following pancreatic Cancer resection: a Randomized Controlled Trial. JAMA. 2010;304(10):1073–81. https://doi.org/10.1001/jama.2010.1275.CrossRefPubMed

15.

Graboyes EM, Divi V, Moore BA. Head and Neck Oncology Is on the National Quality Sidelines No Longer—Put Me in, Coach. JAMA Otolaryngology–Head & Neck Surgery, 2022. 148(8)10.1001/jamaoto.2022.1389.

16.

Aloia TA, et al. Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110(2):107–14. https://doi.org/10.1002/jso.23626.CrossRefPubMedPubMedCentral

17.

Kiong KL et al. Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncology, 2022. 13010.1016/j.oraloncology.2022.105906.

18.

Divi V, et al. Reducing the time from surgery to Adjuvant Radiation Therapy: an Institutional Quality Improvement Project. Otolaryngology–Head Neck Surg. 2018;159(1):158–65. https://doi.org/10.1177/0194599818768254.CrossRef

19.

Hiller JG, et al. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205–18. https://doi.org/10.1038/nrclinonc.2017.194.CrossRefPubMed

20.

Hanin L, Rose J. Suppression of metastasis by primary tumor and acceleration of Metastasis following primary tumor resection: a Natural Law? Bull Math Biol. 2018;80(3):519–39. https://doi.org/10.1007/s11538-017-0388-9.CrossRefPubMed

21.

Kim EY, Hong TH. Changes in total lymphocyte count and neutrophil-to-lymphocyte ratio after curative pancreatectomy in patients with pancreas adenocarcinoma and their prognostic role. J Surg Oncol. 2019;120(7):1102–11. https://doi.org/10.1002/jso.25725.CrossRefPubMed

22.

Tang F, et al. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199–223. https://doi.org/10.1002/ctm2.24.CrossRefPubMedPubMedCentral

23.

Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–71. https://doi.org/10.1038/s41571-019-0175-7.CrossRefPubMed

24.

Cata JP, et al. Inflammation and pro-resolution inflammation after hepatobiliary surgery. World J Surg Oncol. 2017;15(1):152. https://doi.org/10.1186/s12957-017-1220-6.CrossRefPubMedPubMedCentral

25.

Ramirez MF, et al. Innate immune function after breast, lung, and colorectal cancer surgery. J Surg Res. 2015;194(1):185–93. https://doi.org/10.1016/j.jss.2014.10.030.CrossRefPubMed

26.

Velasquez JF, et al. Impaired Immune function in patients undergoing surgery for Bone Cancer. Anticancer Res. 2015;35(10):5461–6.PubMed

27.

Zhang H, et al. Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. Br J Anaesth. 2022;129(2):244–53. https://doi.org/10.1016/j.bja.2022.03.031.CrossRefPubMed

28.

Angka L, et al. Natural killer cell IFNgamma secretion is profoundly suppressed following colorectal Cancer surgery. Ann Surg Oncol. 2018;25(12):3747–54. https://doi.org/10.1245/s10434-018-6691-3.CrossRefPubMed

29.

Karnezis T, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 2012;21(2):181–95. https://doi.org/10.1016/j.ccr.2011.12.026.CrossRefPubMed

30.

Hu Z, et al. Neutrophil extracellular traps induce IL-1beta production by macrophages in combination with lipopolysaccharide. Int J Mol Med. 2017;39(3):549–58. https://doi.org/10.3892/ijmm.2017.2870.CrossRefPubMedPubMedCentral

31.

Vicente D, et al. Impact of epidural analgesia on the systemic biomarker response after hepatic resection. Oncotarget. 2019;10(5):584–94. https://doi.org/10.18632/oncotarget.26549.CrossRefPubMedPubMedCentral

32.

Sun Z, et al. Determining the optimal timing for initiation of adjuvant chemotherapy after resection for stage II and III Colon cancer. Dis Colon Rectum. 2016;59(2):87–93. https://doi.org/10.1097/dcr.0000000000000518.CrossRefPubMed

33.

G Des Guetz, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J cancer (Oxford England: 1990). 2010;46(6):1049–55. https://doi.org/10.1016/j.ejca.2010.01.020.

34.

Seagle B-LL, et al. Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol. 2017;144(2):260–5. https://doi.org/10.1016/j.ygyno.2016.11.022.CrossRefPubMed

35.

Timmermans M, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol. 2018;150(3):446–50. https://doi.org/10.1016/j.ygyno.2018.07.004.CrossRefPubMed

36.

Lohsiriwat V. Enhanced recovery after surgery vs conventional care in emergency colorectal surgery. World J Gastroenterol. 2014;20(38):13950–5. https://doi.org/10.3748/wjg.v20.i38.13950.CrossRefPubMedPubMedCentral

37.

Merkow RP, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7. https://doi.org/10.1097/SLA.0000000000000378.CrossRefPubMed

38.

Ade CJ, et al. Association between serum biomarkers with postoperative complications and Delay of Adjuvant Chemotherapy initiation in ovarian Cancer patients undergoing primary cytoreductive surgery: a pilot study. Nutr Cancer. 2023;75(2):662–9. https://doi.org/10.1080/01635581.2022.2152060.CrossRefPubMed

39.

Kiong KL, et al. Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: impact on return to intended oncologic therapy (RIOT) and survival. Oral Oncol. 2022;130:105906. https://doi.org/10.1016/j.oraloncology.2022.105906.CrossRefPubMed

40.

Hassinger TE, et al. Implementation of an enhanced recovery protocol is Associated with On-Time initiation of Adjuvant Chemotherapy in Colorectal Cancer. Dis Colon Rectum. 2019;62(11):1305–15. https://doi.org/10.1097/DCR.0000000000001486.CrossRefPubMedPubMedCentral

41.

St-Amour P, et al. Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies. Langenbecks Arch Surg. 2020;405(7):959–66. https://doi.org/10.1007/s00423-020-01981-1.CrossRefPubMedPubMedCentral

42.

Nelson DB, et al. Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):279–e2861. https://doi.org/10.1016/j.jtcvs.2019.03.009.CrossRefPubMed

43.

Lillemoe HA, et al. Severe preoperative symptoms Delay Readiness to return to intended oncologic therapy (RIOT) after liver resection. Ann Surg Oncol. 2019;26(13):4548–55. https://doi.org/10.1245/s10434-019-07719-8.CrossRefPubMedPubMedCentral

44.

Naffouje SA, et al. Surgical Approach does not affect return to intended oncologic therapy following pancreaticoduodenectomy for pancreatic adenocarcinoma: a propensity-matched study. Ann Surg Oncol. 2022;29(12):7793–803. https://doi.org/10.1245/s10434-022-12347-w.CrossRefPubMed

45.

Merkow RP, et al. Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg. 2013;258(6):847–53. https://doi.org/10.1097/SLA.0000000000000312.CrossRefPubMed

46.

Cameron KA, et al. Gender disparities in health and healthcare use among older adults. J Womens Health (Larchmt). 2010;19(9):1643–50. https://doi.org/10.1089/jwh.2009.1701.CrossRefPubMed

47.

Lillemoe HA, et al. Detours on the Road to Recovery: what factors Delay Readiness to return to intended oncologic therapy (RIOT) after liver resection for Malignancy? J Gastrointest Surg. 2019;23(12):2362–71. https://doi.org/10.1007/s11605-019-04165-5.CrossRefPubMedPubMedCentral

48.

Graboyes EM, et al. Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. Cancer. 2017;123(14):2651–60. https://doi.org/10.1002/cncr.30651.CrossRefPubMed

49.

Nelson DB, et al. Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2019;158(3):924–9. https://doi.org/10.1016/j.jtcvs.2019.02.129.CrossRefPubMed

50.

Shankaran V, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30(14):1608–14. https://doi.org/10.1200/JCO.2011.37.9511.CrossRefPubMed

51.

Patel MI, et al. Cancer disparities and Health Equity: a Policy Statement from the American Society of Clinical Oncology. J Clin Oncol. 2020;38(29):3439–48. https://doi.org/10.1200/JCO.20.00642.CrossRefPubMedPubMedCentral

52.

Graboyes EM, et al. Barriers to the delivery of Timely, Guideline-Adherent Adjuvant Therapy among patients with Head and Neck Cancer. JCO Oncol Pract. 2020;16(12):e1417–32. https://doi.org/10.1200/OP.20.00271.CrossRefPubMedPubMedCentral

53.

Robert Dood LM, Javier lasala J, Cata G, Mena A, Rodriguez M, Iniesta N, Sheth G, Salvo K, Lu. Pedro Ramirez, Return to intended oncological therapy (RIOT)after surgery for gynecologic cancer in an enhanced recovery after surgery (ERAS) program. Clin Nutr ESPEN. 2017;19:73–99.

54.

Hawn MT, et al. The attributable risk of smoking on surgical complications. Ann Surg. 2011;254(6):914–20. https://doi.org/10.1097/SLA.0b013e31822d7f81.CrossRefPubMed

55.

Choe SI, Finley C. Confronting the negative impact of cigarette smoking on Cancer surgery. Curr Oncol. 2022;29(8):5869–74. https://doi.org/10.3390/curroncol29080463.CrossRefPubMedPubMedCentral

56.

Heiden BT, et al. Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer. Ann Surg. 2023;277(4):e933–40. https://doi.org/10.1097/SLA.0000000000005312.CrossRefPubMed

57.

Amroun K, et al. Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis. Eur J Surg Oncol. 2022;48(2):455–61. https://doi.org/10.1016/j.ejso.2021.09.015.CrossRefPubMed

58.

Sessler DI, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet. 2019;394(10211):1807–15. https://doi.org/10.1016/S0140-6736(19)32313-X.CrossRefPubMed

59.

Xu Z-Z, et al. Epidural anesthesia–analgesia and recurrence-free survival after Lung Cancer surgery: a Randomized Trial. Anesthesiology. 2021;135(3):419–32. https://doi.org/10.1097/aln.0000000000003873.CrossRefPubMed

60.

Enlund M et al. Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. eClinicalMedicine, 2023. 6010.1016/j.eclinm.2023.102037.

61.

Hayden JM, et al. Intraperitoneal ropivacaine reduces time interval to initiation of chemotherapy after surgery for advanced ovarian cancer: randomised controlled double-blind pilot study. Br J Anaesth. 2020;124(5):562–70. https://doi.org/10.1016/j.bja.2020.01.026.CrossRefPubMed

62.

Votta-Velis EG, et al. Regional anaesthesia and cancer metastases: the implication of local anaesthetics. Acta Anaesthesiol Scand. 2013;57(10):1211–29. https://doi.org/10.1111/aas.12210.CrossRefPubMed

63.

Niu L, et al. Association between Intermediate-acting neuromuscular-blocking agents and short-term postoperative outcomes in patients with gastric Cancer. Cancer Manag Res. 2020;12:11391–402. https://doi.org/10.2147/CMAR.S258016.CrossRefPubMedPubMedCentral

64.

McLean DJ, et al. Dose-dependent association between Intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015;122(6):1201–13. https://doi.org/10.1097/aln.0000000000000674.CrossRefPubMed

65.

Dood RL et al. Return to intended oncologic therapy (RIOT) after surgery for gynecologic cancer in an enhanced recovery after surgery (ERAS) program. Clinical Nutrition ESPEN, 2017. 1910.1016/j.clnesp.2017.04.045.

66.

Day RW et al. Patient-Reported Outcomes Accurately Measure the Value of an Enhanced Recovery Program in Liver Surgery. J Am Coll Surg, 2015. 221(6): pp. 1023-30 e1-2; https://doi.org/10.1016/j.jamcollsurg.2015.09.011

67.

Leitao MM, et al. The RECOURSE study: long-term oncologic outcomes Associated with robotically assisted minimally invasive procedures for endometrial, cervical, colorectal, lung, or prostate Cancer: a systematic review and Meta-analysis. Ann Surg. 2023;277(3):387–96. https://doi.org/10.1097/sla.0000000000005698.CrossRefPubMed

68.

nejmoa1604267.

69.

Bilimoria KY, et al. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009;101(12):848–59. https://doi.org/10.1093/jnci/djp107.CrossRefPubMedPubMedCentral

70.

Praiss AM, et al. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: an analysis of a randomized phase II trial. Gynecol Oncol. 2023;171:23–30. https://doi.org/10.1016/j.ygyno.2023.02.003.CrossRefPubMedPubMedCentral

71.

Lau CSM, Chamberlain RS. Enhanced recovery after surgery programs improve patient outcomes and recovery: a Meta-analysis. World J Surg. 2017;41(4):1. https://doi.org/10.1007/s00268-016-3807-4.CrossRef

72.

Ripollés-Melchor J, Abad-Motos A, Zorrilla-Vaca A. Enhanced recovery after surgery (ERAS) in Surgical Oncology. Curr Oncol Rep. 2022;24(9):1177–87. https://doi.org/10.1007/s11912-022-01282-4.CrossRefPubMed

73.

Afonso AM, et al. Enhanced Recovery Programs in an ambulatory Surgical Oncology Center. Anesth Analg. 2021;133(6):1391–401. https://doi.org/10.1213/ANE.0000000000005356.CrossRefPubMedPubMedCentral

74.

Garcia-Nebreda M, et al. Early return to intended oncologic therapy after implementation of an enhanced recovery after surgery pathway for gastric cancer surgery. Langenbeck’s Archives Surg. 2022;407(6):2293–300. https://doi.org/10.1007/s00423-022-02515-7.CrossRef

75.

Lodde G et al. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers (Basel), 2021. 13(10)10.3390/cancers13102319.

76.

Ripollés-Melchor J, et al. Association between Use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery. JAMA Surg. 2019;154(8). https://doi.org/10.1001/jamasurg.2019.0995.

77.

Ripolles-Melchor J, et al. Association between Use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within enhanced recovery after surgery protocol (POWER) study. JAMA Surg. 2019;154(8):725–36. https://doi.org/10.1001/jamasurg.2019.0995.CrossRefPubMedPubMedCentral

78.

Tankou JI, et al. Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers. Int J Gynecologic Cancer. 2021;31(8):1145–53. https://doi.org/10.1136/ijgc-2021-002495.CrossRef

79.

Thomas M, et al. Enhanced recovery pathway in open and minimally invasive colorectal cancer surgery: a prospective study on feasibility, compliance, and outcomes in a high-volume resource limited tertiary cancer center. Langenbeck’s Archives Surg. 2023;408(1):s10100700423–023.CrossRef

80.

Pang Q, et al. Oncologic and long-term outcomes of enhanced recovery after surgery in cancer surgeries - a systematic review. World J Surg Oncol. 2021;19(1):191. https://doi.org/10.1186/s12957-021-02306-2.CrossRefPubMedPubMedCentral

Title: Return to Intended Oncological Therapy: State of the Art and Perspectives
Authors: Nicolas A. Cortes-Mejia
Heather A. Lillemoe
Juan P. Cata
Publication date: 25-09-2024
Publisher: Springer US
Keywords: Cancer Therapy
Cytostatic Therapy
Published in: Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01594-7

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

17-09-2024
Prostate Cancer
News

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

19-09-2024
Diagnostics in Oncology
News

No OS benefit of adding preoperative CRT in gastric cancer

17-09-2024
Gastric Cancer
News

T-DXd supported for breast cancer with brain metastases

17-09-2024
Breast Cancer
News

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Webinar | 01-10-2024 | 12:30 (CEST)

Live event concluded

In this webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Return to Intended Oncological Therapy: State of the Art and Perspectives

Abstract

Purpose of the Review

Findings

Summary

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live event concluded

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose of the Review

Findings

Summary

Please log in to get access to this content

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live event concluded